Jazz Pharmaceuticals plc (JAZZ) Financials
JAZZ Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 11.3 billion | 7.6 billion |
2023-12-31 | 11.4 billion | 7.7 billion |
2023-09-30 | 11.2 billion | 7.7 billion |
2023-06-30 | 11.3 billion | 7.7 billion |
JAZZ Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | 250.3 million | 61.4 million |
2023-12-31 | 157.2 million | 52.9 million |
2023-09-30 | 302.9 million | 56.1 million |
2023-06-30 | 291.0 million | 61.4 million |
JAZZ Net Income
Graph available only for supporters. Become a supporter to see it.
Date | Net Income |
---|---|
2024-03-31 | -14.6 million |
2023-12-31 | 94.2 million |
2023-09-30 | 146.8 million |
2023-06-30 | 104.4 million |
JAZZ Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | - | - | 74.5 million |
2023-12-31 | 1.6 billion | - | 78.7 million |
2023-09-30 | 1.6 billion | - | 78.6 million |
2023-06-30 | 1.4 billion | 5.7 billion | 82.5 million |
JAZZ Shares Outstanding
JAZZ Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 16.9 million | 222.8 million | 351.7 million | - |
2023-12-31 | 10.1 million | 216.6 million | 396.0 million | - |
2023-09-30 | 4.3 million | 234.4 million | 308.3 million | - |
2023-06-30 | 5.7 million | 209.2 million | 340.8 million | - |
JAZZ Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 902.0 million | 95.5 million |
2023-12-31 | 1.0 billion | 258.8 million |
2023-09-30 | 972.1 million | 102.2 million |
2023-06-30 | 957.3 million | 97.5 million |
JAZZ
Price: $105.25
52 week price:
Payout Ratio Range:
Earnings Per Share: 4.83 USD
P/E Ratio: 144.80
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 468012
Ebitda: 136.8 millionMarket Capitalization: 6.9 billion